Market news — every asset we track

Assets

MTVA

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

Aug 19The Globe and Mail

INTS

MTVA

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 MetaVia, Inc. (NASDAQ: MTVA) is currently conducting Part 3 of the Phase 1 study of DA-1726, the company’s oxyntomodulin analog agonist that targets glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), for the treatment of obesity. The

Aug 12Yahoo Finance

MTVA

H.C. Wainwright reiterates MetaVia stock rating on dose milestone

Jul 10Investing.com

MTVA

MetaVia completes dose titration in obesity drug trial

Jul 9Investing.com

MTVA

MetaVia Announces $4 Million At-The-Market Stock Offering

Detailed price information for Metavia Inc (MTVA-Q) from The Globe and Mail including charting and trades.

Jul 3The Globe and Mail

MTVA

This is the newest page. Registered accounts read further back.